3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
30
Nivolumab
12
Carboplatin
6
atezolizumab
5
Trastuzumab
5
aldesleukin
4
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Bevacizumab
4
spartalizumab
3
fludarabine
3
durvalumab
3
Polymerase Chain Reaction
3
Irinotecan
3
Interleukin-2
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
osimertinib
2
enzalutamide
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Colony-Stimulating Factors
×
Thoracic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled